Skip to main
ERAS

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Erasca is a promising precision oncology company with a strong focus on developing effective therapies for RAS/MAPK pathway-driven cancers through three therapeutic strategies. Their collaboration revenue reflects a supportive and collaborative approach to drug development, and with a projected price target of $22 per share based on a solid financial analysis, the company shows great potential for growth in the future. However, risks in regulatory approval, commercialization, clinical development, manufacturing, financial, liability, and intellectual property pose a threat to achieving success. Further clarification on dose strategy by tumor type, safety data, and the planned registrational program will play a vital role in determining the future effectiveness and success of Erasca's pipeline.

Bears say

Erasca is in the clinical stage of drug development for cancer treatments and continues to show promising data in clinical trials; however, the company's pipeline is still far away from potential commercialization. Additionally, the company has incurred significant operating expenses and will need to secure additional funding to continue its development plans. Furthermore, while partnerships with other drug companies are promising, the success of these collaborations is not guaranteed, leading to potential uncertainties in the company's future prospects.

Erasca Inc (ERAS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 9 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.